GATC Health Corp is proud to announce that Dr. Rahul Gupta, MD, MPH, MBA, FACP, has joined the company as its new president. GATC is a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery. Dr. Gupta’s distinguished career in public health leadership, medical innovation, and policy development, brings proven expertise to guide GATC into our next phase of strategic expansion.
Executing GATC Health’s Strategic Vision
In his new role, Dr. Gupta will collaborate with our executive leadership and board of directors to refine and execute the company’s strategic vision. His responsibilities include fostering global partnerships, advancing regulatory education efforts, and championing GATC Health’s advanced AI technology on both national and international stages. His insights will drive commercialization strategies, investor relations, and market development as GATC continues to deliver impactful solutions in AI-driven drug discovery and development.
“Dr. Gupta’s proven expertise and forward-thinking leadership make him the ideal figure to join our team as we steer GATC Health into a new chapter,” said Jayson Uffens, chief technology officer at GATC Health. “Our Multiomics Advanced Technology platform has already demonstrated the ability to dramatically reduce drug discovery timelines, lower costs, and mitigate risk. With Dr. Gupta’s expertise and experience, we are poised to accelerate the delivery of innovative therapies for critical health challenges.”
Creating New Opportunities
Dr. Gupta’s new role with GATC signifies a pivotal moment in the company’s evolution as GATC introduces new multiomics-based solutions for complex health challenges such as opioid use disorder (OUD), PTSD, diabetes, cancer, and more. Additionally, GATC Health is accelerating development through innovative investment partnerships. Dr. Gupta’s leadership will support GATC Health’s efforts to engage federal and state partners, including the FDA, NIH, and members of Congress, positioning the company as a leader in AI-enabled regulatory decision-making, advanced biotech collaboration, and innovation.
Born in India and raised in the United States, Dr. Gupta is a board-certified internist with over 25 years of experience as a practicing physician, public health official, and global health advocate. He has held academic appointments at Georgetown University School of Medicine and Harvard University and served as chief medical and health officer at the March of Dimes, where he oversaw global public health initiatives. Dr. Gupta holds degrees from the University of Delhi, University of Alabama-Birmingham, and the London School of Business and Finance.
“I am excited to join GATC Health at this transformational time for the company and the biotech industry,” said Dr. Gupta. “The Multiomics Advanced Technology platform offers unparalleled potential to transform healthcare delivery and drug discovery. I look forward to collaborating with the talented team to accelerate breakthroughs that improve lives.”
GATC Health Corp. is a technology company transforming drug discovery and development through its AI-driven platform and approach. The company’s validated and proprietary Multiomics Advanced Technology (MAT) simulates human biochemistry’s billions of interactions to rapidly create novel therapeutics, identify and confirm targets, accelerate development, and de-risk drug pipelines by predicting efficacy, safety, and off-target effects.
The company has an office in Morgantown, W.Va.
For more information, visit www.gatchealth.com.
